Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GLP1R | P43220 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4192339 | 0.85 | GLP1R (0.42) | APPHDAC6KCNN3DHFRPFKFB3 | |
| SCHEMBL4196880 | 0.79 | HDAC6 (0.51) | HDAC6KCNN3DHFRPFKFB3LMNA | |
| SCHEMBL21541996 | 0.73 | APP (0.46) | APPDHFRALDH1A1 | |
| SCHEMBL3642615 | 0.71 | APP (0.57) | APPSMN1; SMN2 | |
| SCHEMBL1154650 | 0.70 | DHFR (0.57) | DHFR | |
| SCHEMBL6252449 | 0.67 | KDM4E (0.60) | LMNAALDH1A1SMN1; SMN2DHODH | |
| SCHEMBL15286477 | 0.67 | LMNA (0.55) | HDAC6KCNN3PFKFB3LMNAALDH1A1 | |
| SCHEMBL22872850 | 0.66 | GLP1R (0.49) | HDAC6KCNN3PFKFB3LMNAALDH1A1 | |
| SCHEMBL21524773 | 0.65 | PFKFB3 (0.52) | HDAC6KCNN3DHFRPFKFB3LMNA | |
| SCHEMBL1976205 | 0.65 | PFKFB3 (0.57) | HDAC6KCNN3PFKFB3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048278-A1 | Novel Quinazoline-2,4-Diamine Derivatives and Their Use as Modulators of Small-Conductance Calcium-Activated Potassium Channels | NEUROSEARCH A/S (DK) | 2009-02-19 | — | — | US | claimed |
| US-20090048278-A1 | Novel Quinazoline-2,4-Diamine Derivatives and Their Use as Modulators of Small-Conductance Calcium-Activated Potassium Channels | NEUROSEARCH A/S (DK) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048278-A1 | Novel Quinazoline-2,4-Diamine Derivatives and Their Use as Modulators of Small-Conductance Calcium-Activated Potassium Channels | KCNN2, KCNN3, KCNN1 | APP 1184/4885HDAC6 1504/4885KCNN3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.